Nivolumab - 위키피디아 영어

[25] Autoimmune diabetes similar to diabetes mellitus type 1 may occur in approximately 2% of people treated with nivolumab.[25] In trials for melanoma, the following side effects occurred...

Relatlimab - 위키피디아 영어

Relatlimab is a monoclonal antibody designed for the treatment of melanoma. It is used in combination with nivolumab to treat melanoma. Relatlimab is a Lymphocyte activation gene-3 (LAG-3) inhibitor. It is under development by Bristol-Myers Squibb. It is made using Chinese hamster ovary ce...

Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced - The Lancet

Frank Stephen Hodi, MD · Vanna Chiarion-Sileni, MD · Prof Rene Gonzalez, MD · Prof Jean-Jacques Grob, MD · Prof Piotr Rutkowski, MD · Charles Lance Cowey, MD · Show all authors · Show footnotes

옵디보 Nivolumab (Opdivo)

오늘 알아볼 약은 nivolumab(옵디보)입니다. 결론부터 말씀드리면 이 약은 주로 전이성 흑색종(melanoma)에 효과가 좋은 신약인데 PD-L1의 발현이 있는 소세포폐암(NSCLC)에도 사용 합니다. 물론 가이드상...

Nivolumab plus ipilimumab in advanced melanoma

advanced melanoma. Methods: We administered intravenous doses of nivolumab and ipilimumab in patients every 3 weeks for 4 doses, followed by nivolumab alone every 3 weeks for 4 doses...

Nivolumab 신세포 암종에도 효과 - 한올바이오파마

Nivolumab 신세포 암종에도 효과 면역항암제인 Nivolumab(상품명 Opdivo, BMS사)는 PD-1 저해제 계열 약물로서 흑색종(melanoma), 편평 비소세포성폐암(NSCLC)을 적응증으로 각각 2014년 9월, 2015년...

Nivolumab in Previously Untreated Melanoma without Mutation

Nivolumab was associated with higher rates of objective response than chemotherapy in a phase 3 study involving patients with ipilimumab-refractory metastatic melanoma. The use of nivolumab in prev...

Nivolumab plus Ipilimumab in Advanced Melanoma | New England Journal of Medicine

In patients with melanoma, ipilimumab (an antibody against cytotoxic T-lymphocyte–associated antigen 4 [CTLA-4]) prolongs overall survival, and nivolumab (an antibody against the programmed death 1...

고위험 흑색종에서의 옵디보(니볼루맙)의 치료효과 - 한올바이오파마

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma 2. Clin Cancer Res. 2016 Aug 15;22(16):3992-8. Ipilimumab Combined with Nivolumab: A Standard of Care for the Treatment of Advanced Melanoma? 3. BMS Press release: ...

Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma | New E

Abstract ; Background : Lymphocyte-activation gene 3 (LAG-3) and programmed death 1 (PD-1) are distinct inhibitory immune checkpoints that contribute to T-cell exhaustion. The combination of relatlimab, a LAG-3–blocking antibody, and nivolumab, a PD-1–blocking antibody, has been shown to be safe and to have antitumor activity in patients with previously treated melanoma, but the safety and activity in patients with previously untreated melanoma need investigation. Results : The median progression-free survival was 10.1 months (95% confidenc ...